194 related articles for article (PubMed ID: 37196544)
1. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
2. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
3. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
4. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
6. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo.
Zhou Z; Yu X; Chen Y; Tan X; Liu W; Hua W; Chen L; Zhang W
Clin Transl Oncol; 2023 Apr; 25(4):1067-1079. PubMed ID: 36512305
[TBL] [Abstract][Full Text] [Related]
8. B7-H3-targeted CAR-T cell therapy for solid tumors.
Li G; Wang H; Wu H; Chen J
Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
[TBL] [Abstract][Full Text] [Related]
9. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
[TBL] [Abstract][Full Text] [Related]
10. The role of B7-H3 in tumors and its potential in clinical application.
Feng R; Chen Y; Liu Y; Zhou Q; Zhang W
Int Immunopharmacol; 2021 Dec; 101(Pt B):108153. PubMed ID: 34678689
[TBL] [Abstract][Full Text] [Related]
11. B7-H3-mediated tumor immunology: Friend or foe?
Wang L; Kang FB; Shan BE
Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
[TBL] [Abstract][Full Text] [Related]
12. B7-H3 in Brain Malignancies: Immunology and Immunotherapy.
Guo X; Chang M; Wang Y; Xing B; Ma W
Int J Biol Sci; 2023; 19(12):3762-3780. PubMed ID: 37564196
[TBL] [Abstract][Full Text] [Related]
13. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3.
Kanchan RK; Doss D; Khan P; Nasser MW; Mahapatra S
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188783. PubMed ID: 36028149
[TBL] [Abstract][Full Text] [Related]
14. B7x in cancer immunity and immunotherapy.
Mortezaee K
Int Immunopharmacol; 2023 May; 118():110133. PubMed ID: 37028278
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
[TBL] [Abstract][Full Text] [Related]
16. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.
Liu C; Zhang G; Xiang K; Kim Y; Lavoie RR; Lucien F; Wen T
Cancer Immunol Immunother; 2022 Jul; 71(7):1549-1567. PubMed ID: 34739560
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
Li HY; Chen YL; Deng XN; Li HH; Tan J; Liu GJ; Zheng YJ; Pei M; Peng KT; Yue LL; Chen XJ; Liu Y; Zhao YS; Wang CH
Acta Pharmacol Sin; 2023 Nov; 44(11):2322-2330. PubMed ID: 37328649
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes.
Altan M; Pelekanou V; Schalper KA; Toki M; Gaule P; Syrigos K; Herbst RS; Rimm DL
Clin Cancer Res; 2017 Sep; 23(17):5202-5209. PubMed ID: 28539467
[No Abstract] [Full Text] [Related]
20. Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.
Cai D; Li J; Liu D; Hong S; Qiao Q; Sun Q; Li P; Lyu N; Sun T; Xie S; Guo L; Ni L; Jin L; Dong C
Cell Mol Immunol; 2020 Mar; 17(3):227-236. PubMed ID: 31611650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
